U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Platinum-Refractory Malignant Female Reproductive System Neoplasm

MedGen UID:
1791634
•Concept ID:
C5555193
•
Neoplastic Process

Definition

A malignant female reproductive system neoplasm that progresses during platinum therapy or within one month of completing the last platinum therapy. [from NCI]

Term Hierarchy

CClinical test,  RResearch test,  OOMIM,  GGeneReviews,  VClinVar  
  • CROGVPlatinum-Refractory Malignant Female Reproductive System Neoplasm

Professional guidelines

PubMed

DAGBagM: learning directed acyclic graphs of mixed variables with an application to identify protein biomarkers for treatment response in ovarian cancer.
Chowdhury S, Wang R, Yu Q, Huntoon CJ, Karnitz LM, Kaufmann SH, Gygi SP, Birrer MJ, Paulovich AG, Peng J, Wang P
BMC Bioinformatics 2022 Aug 5;23(1):321. doi: 10.1186/s12859-022-04864-y. PMID: 35931981Free PMC Article
A brief review of the management of platinum-resistant-platinum-refractory ovarian cancer.
Oronsky B, Ray CM, Spira AI, Trepel JB, Carter CA, Cottrill HM
Med Oncol 2017 Jun;34(6):103. Epub 2017 Apr 25 doi: 10.1007/s12032-017-0960-z. PMID: 28444622
Taxanes in ovarian cancer treatment.
Seetalarom K, Kudelka AP, Verschraegen CF, Kavanagh JJ
Curr Opin Obstet Gynecol 1997 Feb;9(1):14-20. PMID: 9090476

Recent clinical studies

Etiology

Avelumab alone or in combination with chemotherapy versus chemotherapy alone in platinum-resistant or platinum-refractory ovarian cancer (JAVELIN Ovarian 200): an open-label, three-arm, randomised, phase 3 study.
Pujade-Lauraine E, Fujiwara K, Ledermann JA, Oza AM, Kristeleit R, Ray-Coquard IL, Richardson GE, Sessa C, Yonemori K, Banerjee S, Leary A, Tinker AV, Jung KH, Madry R, Park SY, Anderson CK, Zohren F, Stewart RA, Wei C, Dychter SS, Monk BJ
Lancet Oncol 2021 Jul;22(7):1034-1046. Epub 2021 Jun 15 doi: 10.1016/S1470-2045(21)00216-3. PMID: 34143970
BRCA Reversion Mutations in Circulating Tumor DNA Predict Primary and Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma.
Lin KK, Harrell MI, Oza AM, Oaknin A, Ray-Coquard I, Tinker AV, Helman E, Radke MR, Say C, Vo LT, Mann E, Isaacson JD, Maloney L, O'Malley DM, Chambers SK, Kaufmann SH, Scott CL, Konecny GE, Coleman RL, Sun JX, Giordano H, Brenton JD, Harding TC, McNeish IA, Swisher EM
Cancer Discov 2019 Feb;9(2):210-219. Epub 2018 Nov 13 doi: 10.1158/2159-8290.CD-18-0715. PMID: 30425037
Bevacizumab combination therapy in recurrent, platinum-refractory, epithelial ovarian carcinoma: A retrospective analysis.
Wright JD, Hagemann A, Rader JS, Viviano D, Gibb RK, Norris L, Mutch DG, Powell MA
Cancer 2006 Jul 1;107(1):83-9. doi: 10.1002/cncr.21969. PMID: 16736514
Topotecan in platinum-resistant epithelial ovarian cancer.
Karabulut B, Sezgin C, Terek MC, Uslu R, Sanli UA, Akman L, Ozsaran A, Dikmen Y, Goker E
Chemotherapy 2005 Oct;51(6):347-51. Epub 2005 Oct 14 doi: 10.1159/000088959. PMID: 16227688
Chlorambucil for platinum-refractory ovarian cancer.
Taylor AE, Gore ME
Clin Oncol (R Coll Radiol) 1994;6(3):177-8. doi: 10.1016/s0936-6555(94)80058-8. PMID: 8086353

Diagnosis

DAGBagM: learning directed acyclic graphs of mixed variables with an application to identify protein biomarkers for treatment response in ovarian cancer.
Chowdhury S, Wang R, Yu Q, Huntoon CJ, Karnitz LM, Kaufmann SH, Gygi SP, Birrer MJ, Paulovich AG, Peng J, Wang P
BMC Bioinformatics 2022 Aug 5;23(1):321. doi: 10.1186/s12859-022-04864-y. PMID: 35931981Free PMC Article
Avelumab alone or in combination with chemotherapy versus chemotherapy alone in platinum-resistant or platinum-refractory ovarian cancer (JAVELIN Ovarian 200): an open-label, three-arm, randomised, phase 3 study.
Pujade-Lauraine E, Fujiwara K, Ledermann JA, Oza AM, Kristeleit R, Ray-Coquard IL, Richardson GE, Sessa C, Yonemori K, Banerjee S, Leary A, Tinker AV, Jung KH, Madry R, Park SY, Anderson CK, Zohren F, Stewart RA, Wei C, Dychter SS, Monk BJ
Lancet Oncol 2021 Jul;22(7):1034-1046. Epub 2021 Jun 15 doi: 10.1016/S1470-2045(21)00216-3. PMID: 34143970
BRCA Reversion Mutations in Circulating Tumor DNA Predict Primary and Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma.
Lin KK, Harrell MI, Oza AM, Oaknin A, Ray-Coquard I, Tinker AV, Helman E, Radke MR, Say C, Vo LT, Mann E, Isaacson JD, Maloney L, O'Malley DM, Chambers SK, Kaufmann SH, Scott CL, Konecny GE, Coleman RL, Sun JX, Giordano H, Brenton JD, Harding TC, McNeish IA, Swisher EM
Cancer Discov 2019 Feb;9(2):210-219. Epub 2018 Nov 13 doi: 10.1158/2159-8290.CD-18-0715. PMID: 30425037
Role of pegylated liposomal doxorubicin (Caelyx) in the treatment of relapsing ovarian cancer.
Pérez-López ME, Curiel T, Gómez JG, Jorge M
Anticancer Drugs 2007 Jun;18(5):611-7. doi: 10.1097/CAD.0b013e32802623fc. PMID: 17414631
Ovarian cancer.
Colombo N, Van Gorp T, Parma G, Amant F, Gatta G, Sessa C, Vergote I
Crit Rev Oncol Hematol 2006 Nov;60(2):159-79. Epub 2006 Oct 2 doi: 10.1016/j.critrevonc.2006.03.004. PMID: 17018256

Therapy

Avelumab alone or in combination with chemotherapy versus chemotherapy alone in platinum-resistant or platinum-refractory ovarian cancer (JAVELIN Ovarian 200): an open-label, three-arm, randomised, phase 3 study.
Pujade-Lauraine E, Fujiwara K, Ledermann JA, Oza AM, Kristeleit R, Ray-Coquard IL, Richardson GE, Sessa C, Yonemori K, Banerjee S, Leary A, Tinker AV, Jung KH, Madry R, Park SY, Anderson CK, Zohren F, Stewart RA, Wei C, Dychter SS, Monk BJ
Lancet Oncol 2021 Jul;22(7):1034-1046. Epub 2021 Jun 15 doi: 10.1016/S1470-2045(21)00216-3. PMID: 34143970
Role of pegylated liposomal doxorubicin (Caelyx) in the treatment of relapsing ovarian cancer.
Pérez-López ME, Curiel T, Gómez JG, Jorge M
Anticancer Drugs 2007 Jun;18(5):611-7. doi: 10.1097/CAD.0b013e32802623fc. PMID: 17414631
Topotecan in platinum-resistant epithelial ovarian cancer.
Karabulut B, Sezgin C, Terek MC, Uslu R, Sanli UA, Akman L, Ozsaran A, Dikmen Y, Goker E
Chemotherapy 2005 Oct;51(6):347-51. Epub 2005 Oct 14 doi: 10.1159/000088959. PMID: 16227688
ATP chemosensitivity testing in ovarian and breast cancer: early clinical trials.
Kurbacher CM, Grecu OM, Stier U, Gilster TJ, Janát MM, Untch M, Konecny G, Bruckner HW, Cree IA
Recent Results Cancer Res 2003;161:221-30. doi: 10.1007/978-3-642-19022-3_17. PMID: 12528810
New drugs in gynecologic cancer.
Daud A, Munster P, Munster P, Spriggs DR
Curr Treat Options Oncol 2001 Apr;2(2):119-28. doi: 10.1007/s11864-001-0054-0. PMID: 12057130

Prognosis

BRCA Reversion Mutations in Circulating Tumor DNA Predict Primary and Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma.
Lin KK, Harrell MI, Oza AM, Oaknin A, Ray-Coquard I, Tinker AV, Helman E, Radke MR, Say C, Vo LT, Mann E, Isaacson JD, Maloney L, O'Malley DM, Chambers SK, Kaufmann SH, Scott CL, Konecny GE, Coleman RL, Sun JX, Giordano H, Brenton JD, Harding TC, McNeish IA, Swisher EM
Cancer Discov 2019 Feb;9(2):210-219. Epub 2018 Nov 13 doi: 10.1158/2159-8290.CD-18-0715. PMID: 30425037
Role of pegylated liposomal doxorubicin (Caelyx) in the treatment of relapsing ovarian cancer.
Pérez-López ME, Curiel T, Gómez JG, Jorge M
Anticancer Drugs 2007 Jun;18(5):611-7. doi: 10.1097/CAD.0b013e32802623fc. PMID: 17414631
Topotecan in platinum-resistant epithelial ovarian cancer.
Karabulut B, Sezgin C, Terek MC, Uslu R, Sanli UA, Akman L, Ozsaran A, Dikmen Y, Goker E
Chemotherapy 2005 Oct;51(6):347-51. Epub 2005 Oct 14 doi: 10.1159/000088959. PMID: 16227688
ATP chemosensitivity testing in ovarian and breast cancer: early clinical trials.
Kurbacher CM, Grecu OM, Stier U, Gilster TJ, Janát MM, Untch M, Konecny G, Bruckner HW, Cree IA
Recent Results Cancer Res 2003;161:221-30. doi: 10.1007/978-3-642-19022-3_17. PMID: 12528810
New drugs in gynecologic cancer.
Daud A, Munster P, Munster P, Spriggs DR
Curr Treat Options Oncol 2001 Apr;2(2):119-28. doi: 10.1007/s11864-001-0054-0. PMID: 12057130

Clinical prediction guides

Extraperitoneal response to intraperitoneal immunotherapy with catumaxomab in a patient with cutaneous lymphangiosis carcinomatosa from ovarian cancer: a case report and review of the literature.
Woopen H, Pietzner K, Darb-Esfahani S, Oskay-Oezcelik G, Sehouli J
Med Oncol 2012 Dec;29(5):3416-20. Epub 2012 Jun 29 doi: 10.1007/s12032-012-0285-x. PMID: 22744709
Role of pegylated liposomal doxorubicin (Caelyx) in the treatment of relapsing ovarian cancer.
Pérez-López ME, Curiel T, Gómez JG, Jorge M
Anticancer Drugs 2007 Jun;18(5):611-7. doi: 10.1097/CAD.0b013e32802623fc. PMID: 17414631
Bevacizumab combination therapy in recurrent, platinum-refractory, epithelial ovarian carcinoma: A retrospective analysis.
Wright JD, Hagemann A, Rader JS, Viviano D, Gibb RK, Norris L, Mutch DG, Powell MA
Cancer 2006 Jul 1;107(1):83-9. doi: 10.1002/cncr.21969. PMID: 16736514
Tamoxifen in platinum-refractory ovarian cancer: a Gynecologic Oncology Group Ancillary Report.
Markman M, Iseminger KA, Hatch KD, Creasman WT, Barnes W, Dubeshter B
Gynecol Oncol 1996 Jul;62(1):4-6. doi: 10.1006/gyno.1996.0181. PMID: 8690289
A trial of lobaplatin (D-19466) in platinum-resistant ovarian cancer.
Kavanagh JJ, Edwards CL, Freedman RS, Finnegan MB, Balat O, Tresukosol D, Burk K, Loechner S, Hord M, Franklin JL
Gynecol Oncol 1995 Jul;58(1):106-9. doi: 10.1006/gyno.1995.1191. PMID: 7789874

Recent systematic reviews

Luteinising hormone releasing hormone (LHRH) agonists for the treatment of relapsed epithelial ovarian cancer.
Wuntakal R, Seshadri S, Montes A, Lane G
Cochrane Database Syst Rev 2016 Jun 29;2016(6):CD011322. doi: 10.1002/14651858.CD011322.pub2. PMID: 27356090Free PMC Article
Topotecan, pegylated liposomal doxorubicin hydrochloride and paclitaxel for second-line or subsequent treatment of advanced ovarian cancer: a systematic review and economic evaluation.
Main C, Bojke L, Griffin S, Norman G, Barbieri M, Mather L, Stark D, Palmer S, Riemsma R
Health Technol Assess 2006 Mar;10(9):1-132. iii-iv. doi: 10.3310/hta10090. PMID: 16545208

Supplemental Content

Table of contents

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...